Evidence memo

AOD-9604

Also tracked as: HGH fragment 176-191 claims

An obesity-claim peptide fragment with old clinical development signals, limited modern clinical relevance, and regulatory caution.

Early human signal Safety watch

Evidence status

High interest / low certainty. Evidence level: Early human signal.

Whether older obesity-development data support current body-composition claims made online.

It is marketed around a simple fat-loss story, but the clinical-development history is much less compelling than the marketing narrative.

There are early human and regulatory-review materials, but not an approved obesity medicine or strong modern outcomes package.

Clinical relevance, product identity, and whether claimed outcomes persist under controlled conditions.

Regulatory status and compounding review matter. Avoid claims that imply approved therapeutic use.

FDA review updates, independent trial evidence, and product characterization standards.

A watch item because the marketing is cleaner than the evidence.

FDA

U.S. Food and Drug Administration · 2026 briefing material

Regulatory review material; used for caution around identity, evidence, and compounding status.

FDA

U.S. Food and Drug Administration · Current FDA page

Regulatory source for compounding-safety watch items; status should be rechecked before publication.